MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from exercise ofwarrants$4,639K Proceeds from issuance ofdebt$1,400K Proceeds from issuance ofwarrants$567K Proceeds from issuance ofcommon stock$342K Net cash provided byfinancing activities$6,109K Canceled cashflow$810K Net increase(decrease) in cash and cash...$81K Canceled cashflow$6,028K Payments for issuancecosts$487K Reduction of debtliability$309K Reduction of finance leaseliability$14K Fair value of commonstock issued to...$514K Depreciation andamortization$454K Other liabilities$385K Accounts payable$318K Stock-based compensationexpense$151K Accrued expenses$125K Paid-in-kind interestexpense on promissory...$40K Operating leaseliabilities, net$18K Contract liability$16K Net cash used inoperating activities-$6,010K Net cash used ininvesting activities-$18K Canceled cashflow$2,021K Net loss-$7,751K Acquisitions of property andequipment$18K Accounts receivable,$188K Prepaid expenses andother current assets$166K
Cash Flow

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc. (VVOS)

source: myfinsight.com